Gain Therapeutics Reports $5.8 Million Net Loss in Q2 2025, Sees Decrease in Operating Expenses

Gain Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $5.8 million, a decrease from the $8.1 million loss recorded in the same period last year. For the first half of 2025, the company reported a net loss of $10.3 million, down from $12.2 million in the first half of 2024. The reduction in losses is attributed to a significant decrease in operating expenses, which totaled $5.1 million for the quarter, compared to $8.2 million in the prior year. This decline was driven by lower research and development costs, which fell to $2.8 million from $4.4 million, and general and administrative expenses, which decreased to $2.3 million from $3.7 million.

The company’s total assets as of June 30, 2025, were reported at $9.8 million, a decline from $12.1 million at the end of 2024. Current liabilities increased to $5.2 million from $3.9 million, primarily due to a rise in accounts payable, which surged to $2.7 million from $0.9 million. The accumulated deficit also widened to $91.5 million from $81.2 million at the end of 2024. Gain Therapeutics ended the quarter with cash and cash equivalents of $6.7 million, down from $10.4 million at the end of the previous year.

In terms of strategic developments, Gain Therapeutics completed a public offering in July 2025, raising $7.0 million in gross proceeds, which included the exercise of an over-allotment option that added an additional $1.0 million. The company has also been actively utilizing its Magellan™ drug discovery platform to advance its clinical-stage product candidate, GT-02287, aimed at treating Parkinson’s disease. The company announced the completion of enrollment in its ongoing Phase 1b clinical study, with results expected in the fourth quarter of 2025.

Operationally, Gain Therapeutics has focused on optimizing its research and development expenditures, which have been offset by contributions from research grants. The company recorded a reduction in research and development expenses due to the recognition of grant income and tax credits. The company’s employee headcount has remained stable, with ongoing efforts to manage costs effectively while advancing its clinical programs.

Looking ahead, Gain Therapeutics anticipates the need for additional financing to support its operations beyond the first quarter of 2026. The company is exploring various avenues for funding, including public and private equity offerings, collaborations, and strategic partnerships. However, there remains substantial doubt about its ability to continue as a going concern without securing further capital. The company’s management is actively reviewing its cost structure to enhance operational efficiency and reduce cash burn rates.